As of 30 Sep 2025, 59 institutional investors reported holding $726,382,500 in principal (par value) of HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0.
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | $113,000 | $122,721 | +$17,701 | 108.1% | 4 |
| 2025 Q3 | $726,382,500 | $834,806,788 | +$105,581,455 | 114.78% | 59 |
| 2025 Q2 | $728,633,184 | $726,115,830 | +$9,607,370 | 99.57% | 64 |
| 2025 Q1 | $707,502,041 | $750,572,002 | -$21,159,427 | 105.81% | 57 |
| 2024 Q4 | $713,351,051 | $682,649,093 | +$30,765,855 | 95.39% | 57 |
| 2024 Q3 | $685,848,882 | $688,553,098 | -$133,842,993 | 100.08% | 54 |
| 2024 Q2 | $833,277,781 | $795,939,589 | +$12,847,273 | 95.33% | 58 |
| 2024 Q1 | $819,088,507 | $726,898,751 | -$345,457 | 88.67% | 61 |
| 2023 Q4 | $815,214,254 | $706,534,402 | +$11,603,534 | 86.44% | 64 |
| 2023 Q3 | $799,411,199 | $679,095,809 | +$6,210,490 | 84.45% | 65 |
| 2023 Q2 | $794,335,832 | $662,252,900 | +$19,666,070 | 83.28% | 67 |
| 2023 Q1 | $836,537,369 | $710,137,045 | +$46,468,623 | 84.78% | 62 |
| 2022 Q4 | $676,406,024 | $656,553,304 | -$264,456,865 | 97.14% | 53 |
| 2022 Q3 | $730,524,195 | $620,620,688 | +$5,561,573 | 85.0% | 48 |
| 2022 Q2 | $712,881,662 | $631,436,377 | +$142,081,055 | 88.39% | 50 |
| 2022 Q1 | $543,043,884 | $476,655,665 | +$476,655,665 | 87.73% | 46 |